Study compares FAPI, FDG PET agents in pancreatic cancer


Mayo Clinic researchers will use a $3.3 million grant from the National Cancer Institute to compare the efficacy of Ga-68 FAPI-46 and F-18 FDG PET radiotracers in detecting pancreatic cancer. "In view of the dismal prognosis of pancreatic cancer, novel treatment strategies are urgently needed to improve outcomes. FAPI PET could lead to peptide receptor radionuclide therapy for pancreatic cancer, which will be very exciting," said researcher Dr. Mark Truty.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily email newsletter. It provides the latest news and information to save you time and keep you informed on our profession.